February 10, 2005
by Brian Turner
GlaxoSmithKline loses to generics
by Brian Turner
European biotech giant, GlaxoSmithKline, reported a profit fall of 9% in 2004 to a total of £6.2bn ($11.5bn).
However, despite losing out around £1.5 billion to generic drugs markets, GlaxoSmithKline still saw 1% overall growth, and expects to improve on sales revenue over 2005.
Story link: GlaxoSmithKline loses to generics
Related Stories:
- No related posts
Previous: « LSE bid speculation continues
Next: Fair Eire markets »
Visited 549 times, 1 so far today